To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics.
Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.
Funding Rounds (3) - $61.9MUpdate
OrbiMed is a healthcare-dedicated investment firm, with approximately $5 billion in assets under...
Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life...
Crédit Agricole Private Equity supports companies at all stages of their growth and expansion,...
LSP BioVentures is a venture capital fund focused on opportunities in the life science arena.
Venture capital Firm
PMV is an independent investment company. It invests in the economic fabric of Flanders. In so...
Private Equity Bank
Dr Molewaterplein 50